GCLSX
Price
$25.50
Change
+$0.39 (+1.55%)
Updated
Nov 21 closing price
Net Assets
572.69M
VIVIX
Price
$72.32
Change
+$0.97 (+1.36%)
Updated
Nov 21 closing price
Net Assets
207.95B
Interact to see
Advertisement

GCLSX vs VIVIX

Header iconGCLSX vs VIVIX Comparison
Open Charts GCLSX vs VIVIXBanner chart's image
Goldman Sachs Large Cp Val Insghts Svc
Price$25.50
Change+$0.39 (+1.55%)
VolumeN/A
Net Assets572.69M
Vanguard Value Index I
Price$72.32
Change+$0.97 (+1.36%)
VolumeN/A
Net Assets207.95B
GCLSX vs VIVIX Comparison Chart in %
View a ticker or compare two or three
VS
GCLSX vs. VIVIX commentary
Nov 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GCLSX is a Buy and VIVIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VIVIX has more cash in the bank: 208B vs. GCLSX (573M). VIVIX pays higher dividends than GCLSX: VIVIX (2.10) vs GCLSX (0.66). GCLSX was incepted earlier than VIVIX: GCLSX (27 years) vs VIVIX (27 years). GCLSX (1.16) is less costly to investors than VIVIX (0.04). GCLSX is a more actively managed with annual turnover of: 206.00 vs. VIVIX (9.00). GCLSX has a lower initial minimum investment than VIVIX: GCLSX (0) vs VIVIX (5000000). VIVIX annual gain was more profitable for investors over the last year : 3.84 vs. GCLSX (-7.08). VIVIX return over 5 years is better than : 63.33 vs. GCLSX (24.62).
GCLSXVIVIXGCLSX / VIVIX
Total Expense Ratio1.060.042,650%
Annual Report Gross Expense Ratio1.160.042,900%
Fund Existence27 years27 years-
Gain YTD9.8579.611103%
Front LoadN/AN/A-
Min. Initial Investment05000000-
Min. Initial Investment IRAN/AN/A-
Net Assets573M208B0%
Annual Yield % from dividends0.662.1031%
Returns for 1 year-7.083.84-184%
Returns for 3 years17.3228.8060%
Returns for 5 years24.6263.3339%
Returns for 10 years63.48123.4051%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VALU36.910.73
+2.02%
Value Line
HALO70.341.37
+1.99%
Halozyme Therapeutics
VVX52.260.10
+0.19%
V2X
POLEU10.65N/A
N/A
Andretti Acquisition Corp
NEPH4.87-0.05
-1.02%
Nephros